Skip to main content

Table 2 Final model for the occurrence of MTX side-effects

From: Concomitant prednisone may alleviate methotrexate side-effects in rheumatoid arthritis patients

A. Overall model

 

OR

95% CI

P-value

Use of prednisone

0.54

0.38–0.77

0.001

Male sex

0.53

0.37–0.77

0.001

Age (years)

0.98

0.97–0.99

0.001

MTXa dose (mg)

1.03

1.01–1.04

0.001

DAS28b

1.05

0.96–1.14

0.307

ASTc at baseline (U/L)

1.02

1.00–1.04

0.082

ALTd at baseline (U/L)

1.01

1.00–1.02

0.069

Time (months)

0.93

0.89–0.98

0.004

Time2 (months)

1.00

1.00–1.00

0.010

Intercept

0.28

0.13–0.62

0.002

B. Model stratified by sex

 

Males

Females

OR

95% CI

P-value

OR

95% CI

P-value

Use of prednisone

0.84

0.46–1.55

0.586

0.42

0.28–0.63

 < 0.001

Age (years)

0.97

0.95–0.99

0.007

0.98

0.97–1.00

0.009

MTXa dose (mg)

1.05

1.02–1.07

 < 0.001

1.02

1.00–1.03

0.066

DAS28b

0.97

0.83–1.13

0.711

1.12

1.02–1.24

0.023

ASTc at baseline (U/L)

1.00

0.97–1.04

0.906

1.02

1.00–1.05

0.055

ALTd at baseline (U/L)

1.02

1.01–1.04

0.011

1.00

0.99–1.01

0.567

Time (months)

0.93

0.88–0.98

0.013

0.95

0.90–1.01

0.097

Time2 (months)

1.00

1.00–1.00

0.026

1.00

1.00–1.00

0.131

Intercept

0.19

0.04–0.88

0.033

0.25

0.09–0.69

0.007

  1. Bold signify the primary outcome of the analysis
  2. aMethotrexate
  3. bDisease Activity Score assessing 28 joints
  4. cAspartate transaminase d. Alanine transaminase
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us